glp-1 obesity drug news october 2025 Weight-loss drugs such as Ozempic were in the headlines a lot in – and patent protections for these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ Alarming rise in weight loss

By week 16, a larger proportion of AXA1125-treated subjects (3540%) than those in the placebo group (825%) reached clinically relevant thresholds for MRI-PDFF reductions of 30%, ALT reductions of 17 IU/L, and cT1 reductions of 80 ms

This ensures your volume measurement is accurate

Through binding to these sequences, m-MITF directly activates the transcription of hundreds of genes in the melanocytic lineage and controls melanocyte proliferation, differentiation, survival, pigment production and various additional processes

Grce sa capacit neutraliser les substances nocives, le glutathion est essentiel pour maintenir une bonne sant et vitalit

The potential nephroprotective mechanisms of GLP-1RAs likely involve GLP-1RA-mediated improvements of conventional risk factors for diabetic kidney disease (control of glycaemia, postprandial lipid level, body weight and blood pressure), but perhaps also direct effects on the kidneys

It is hypothesized that with continued use and continued titration of insulin, superior reductions in A1C would be seen with an intensive insulin therapy compared to GLP-1 RAs